An interventional study of Spinery System in Vertebral Metastasis, sponsored by Axon srl. Completed at 5 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-28.
Sponsored by Axon srl · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 352 studies in Neoplasm Metastasis with a site in Italy — 71 open to participants now, 115 under way, 40 of them phase 3. Neoplasm Metastasis · Italy.
Among the 352 studies in Neoplasm Metastasis with a site in Italy, this one is the 245th largest by enrollment of the 297 interventional ones that give a count, is one of 27 that started in 2022, is one of 26 with no phase, and was the 274th registered.
4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.
Browse Neoplasm Metastasis studies →71 of the 352 studies in Neoplasm Metastasis with a site in Italy are open now. Recruiting first, the newest first:
Azienda Ospedaliero-Universitaria di Modena · Sites in Italy
Ages 18+
AstraZeneca · Sites in Italy, United States, France and 6 more countries
Ages 18–130
Niguarda Hospital · Sites in Italy
Ages 18+
Regeneron Pharmaceuticals · Sites in Italy, United States, Australia and 3 more countries
Ages 18+
Crescent Biopharma, Inc. · Sites in Italy, United States, Australia and 7 more countries
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
352 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 65 · Phase 2 123 · Phase 3 123 · Phase 4 4
First in 1992; this study’s year is marked. 27 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 52 is close to the median of 50 across 3,276 interventional studies indexed under Neoplasm Metastasis.
Median enrollment 205 across the 297 interventional studies, 225 across the 50 observational. Of the 204 that completed or were terminated, 105 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
226 of 352 have an industry lead sponsor. The 10 most frequent:
Axon srl is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Axon srl has 1 study filed under Neoplasm Metastasis — fewer than ten, so there is no comparison to draw.
28 of the studies in Neoplasm Metastasis with a site in Italy that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07221734Phase 3mAbxience Research S.L.Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB11 Versus EU-/US-Opdivo® in Subjects With Previously Untreated Advanced [Unresectable or Metastatic] Melanoma | 2027-04 |
| NCT04784715Phase 3AstraZenecaTrastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09) | 2027-05-03 |
| NCT06103864Phase 3AstraZenecaA Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) | 2027-07-28 |
| NCT06064877Phase 3AVEO Pharmaceuticals, Inc.A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma | 2027-08 |
| NCT07044336Phase 3AstraZenecaPuxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | 2027-10-15 |
Add all 28 to your calendar (.ics) → With an account.
Among the 352 studies in Neoplasm Metastasis with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The SPARTA study (Spinery® Radiofrequency Ablation Device Study) is a prospective, multicenter, single-arm clinical investigation designed to evaluate the safety, performance, and efficacy of the Spinery® RF Generator and its sterile single-use accessories for the palliative treatment of painful bone metastases.
Adult patients with metastatic lesions involving the vertebral bodies, sacrum, iliac crest, or peri-acetabulum who were not candidates for, or had failed, standard therapies underwent percutaneous radiofrequency ablation with the investigational device.
A total of 52 participants were enrolled across five Italian centers and were assessed at baseline, post-procedure, and during follow-up visits at 1, 3, and 12 months.
Endpoints include evaluation of pain reduction, quality of life, usability, and procedural safety.
Bone metastases are a frequent cause of pain and disability in patients with advanced cancer, often leading to impaired mobility and reduced quality of life. Conventional treatments such as systemic analgesics, radiotherapy, or chemotherapy may not always achieve adequate symptom control, particularly in patients with recurrent or resistant disease.
Radiofrequency (RF) ablation has emerged as a minimally invasive, image-guided procedure that induces controlled thermal necrosis within metastatic lesions, potentially reducing pain by interrupting nociceptive pathways and stabilizing the affected bone.
The SPARTA study was designed to collect clinical data on the Spinery® RF Generator and its sterile single-use accessories, a bipolar/monopolar RF ablation technology intended for percutaneous use in bone metastases.
This clinical investigation follows a prospective, multicenter, single-arm design without a control group; data are compared with published evidence available in the literature to contextualize safety and performance outcomes.
A total of 52 patients were enrolled across five Italian centers. Eligible participants were adults with painful metastatic bone tumors located in the thoracic or lumbar vertebrae, sacrum, iliac crest, or peri-acetabulum.
Following informed consent and baseline assessments, each patient underwent image-guided RF ablation using the Spinery® device. The procedure allowed the treating physician to select monopolar or bipolar cooled electrodes according to lesion size and location.
Participants were monitored within 24 hours post-procedure and followed at 1, 3, and 12 months after treatment.
Study assessments include:
The primary objectives are:
The secondary objectives are:
This clinical investigation is conducted in compliance with ethical principles of Good Clinical Practice and applicable regulatory requirements.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this single-arm study underwent percutaneous radiofrequency ablation of painful bone metastases using the Spinery System, consisting of the Spinery® RF Generator, the sterile single-use Spinery® Kit, and the sterile single-use Spinery® Cooling Connection. The procedure was performed according to the study protocol, with follow-up visits scheduled at 1, 3, and 12 months to assess pain reduction, safety, usability, and quality of life.
Device: Spinery System
Radiofrequency ablation of bone metastases performed with the Spinery System, a radiofrequency generator with dedicated sterile, single-use accessories (electrode kit and cooling connection).
Also known as: Spinery® RF Generator, the sterile single-use Spinery® Kit, and the sterile single-use Spinery® Cooling Connection
Change From Baseline in Worst Pain and Quality of Life Scores at 3 Months Using the Brief Pain Inventory (BPI) and EQ-5D-5L Questionnaires
Pain severity and health-related quality of life were evaluated using two validated questionnaires: * Brief Pain Inventory (BPI): Participants rated their worst pain in the last 24 hours for each treated lesion site (thoracic, lumbar, peri-acetabulum, iliac crest, sacrum) on an 11-point numeric scale from 0 (no pain) to 10 (pain as bad as you can imagine). Higher scores indicate worse pain. The change in BPI Worst Pain Score was calculated as the average reduction from baseline to the 3-month visit. * EQ-5D-5L: Participants reported their overall health status across five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each rated on five levels of severity. Responses were converted into a utility index ranging from -0.594 (worst health state) to 1.000 (best health state), where higher scores indicate better quality of life. The EQ-5D-5L visual analogue scale (VAS) ranges from 0 (worst imaginable health) to 100 (best imaginable health).
Time frame: Baseline and 3-month follow-up
Number and Percentage of Participants Who Successfully Completed the Spinery® RF Ablation Procedure
The number and percentage of participants who successfully completed the Spinery® RF ablation procedure per protocol. Completion is defined as participants who underwent the full planned treatment without premature discontinuation or technical interruption. Results are expressed as the count and percentage of the total number of treated participants.
Time frame: Post-Procedure (primary evaluation point)
Participants were recruited between July 2022 and Nov 2023 at 5 clinical sites. Eligible participants were adult who met all inclusion/exclusion criteria specified in the protocol. Recruitment followed standard informed consent procedures at each site.
| Milestone | Spinery RF Ablation Treatment Group |
|---|---|
| Started | 51 |
| Completed | 51 |
| Not completed | 0 |
| Milestone | Spinery RF Ablation Treatment Group |
|---|---|
| Started | 51 |
| Completed | 41 |
| Not completed | 10 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Lost to follow-up | 4 |
| Withdrew: Death | 5 |
| Milestone | Spinery RF Ablation Treatment Group |
|---|---|
| Started | 41 |
| Completed | 26 |
| Not completed | 15 |
| Withdrew: Lost to follow-up | 6 |
| Withdrew: Death | 8 |
| Withdrew: Withdrawal by subject | 1 |
Pain severity and health-related quality of life were evaluated using two validated questionnaires: * Brief Pain Inventory (BPI): Participants rated their worst pain in the last 24 hours for each treated lesion site (thoracic, lumbar, peri-acetabulum, iliac crest, sacrum) on an 11-point numeric scale from 0 (no pain) to 10 (pain as bad as you can imagine). Higher scores indicate worse pain. The change in BPI Worst Pain Score was calculated as the average reduction from baseline to the 3-month visit. * EQ-5D-5L: Participants reported their overall health status across five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each rated on five levels of severity. Responses were converted into a utility index ranging from -0.594 (worst health state) to 1.000 (best health state), where higher scores indicate better quality of life. The EQ-5D-5L visual analogue scale (VAS) ranges from 0 (worst imaginable health) to 100 (best imaginable health).
| points on a numeric scale | 3-Months Follow-up |
|---|---|
| Change in Worst Pain Score (BPI, 0-10 scale; higher = worse pain) | 3.4 ± 2.8 |
| Change in Quality of Life (EQ-5D-5L VAS, 0-100 scale; higher = better health status) | 65.2 ± 19.0 |
The number and percentage of participants who successfully completed the Spinery® RF ablation procedure per protocol. Completion is defined as participants who underwent the full planned treatment without premature discontinuation or technical interruption. Results are expressed as the count and percentage of the total number of treated participants.
| Participants | Post-Procedure |
|---|---|
| Number and Percentage of Participants Who Successfully Completed the Spinery® RF Ablation Procedure | 51 |
Collected over Serious and Other (Not Including Serious) Adverse Events were assessed from the day of the Spinery® RF Ablation procedure through the 3-month follow-up visit. All-Cause Mortality was assessed from the day of the procedure through the 12-month follow-up visit.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Participants | 13/51 (25.5%) | 13/51 (25.5%) | 1/51 (2%) |
| Event | All Participants |
|---|---|
| DeathGeneral disorders | 13/51 |
| Event | All Participants |
|---|---|
| New metastasis (right scapula)Neoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/51 |
Baseline characteristics were assessed in all participants who started the Spinery RF Ablation procedure (N=51) prior to treatment. One participant withdrew consent after enrollment and before treatment allocation and was not included in the baseline analyses.
| Age, Categorical(Participants) | BaseLine |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 24 |
| >=65 years | 27 |
| Sex: Female, Male(Participants) | BaseLine |
|---|---|
| Female | 31 |
| Male | 20 |
| Race and Ethnicity Not Collected(Participants) | BaseLine |
|---|
| Primary Tumor Site(participants) | BaseLine |
|---|---|
| Breast | 19 |
| Lungs | 12 |
| Prostate | 4 |
| Bladder | 1 |
| Kidney | 4 |
| Colon | 1 |
| Lynphatic system | 1 |
| Lymphomas | 1 |
| Sarcoma | 1 |
| Adeno Carcinoma | 1 |
| Intestine | 1 |
| Chest | 1 |
| Liver | 1 |
| Pancreas | 1 |
| Other | 1 |
| Target Lesion Location(Participants) | BaseLine |
|---|---|
| Vertebral Body | 27 |
| Sacrum | 10 |
| Iliac Crest | 7 |
| Pari-acetabulum | 7 |
| Pain Score at Baseline (BPI)(units on a scale) | BaseLine |
|---|---|
| Mean | 7.8 ± 1.6 |
| EQ-5D-5L(units on a scale) | BaseLine |
|---|---|
| Mean | 42.8 ± 16.8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2022 to primary completion in Feb 2024, 19 months.
Results were first posted in Nov 2025, 1 year 9 months after primary completion.
Of 320 interventional studies with no phase under Neoplasm Metastasis, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 91. This study's 19 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Axon srl